Development and validation of the MMCD score to predict kidney replacement therapy in COVID-19 patients
Nenhuma Miniatura disponível
Data
2022-12-01
Autores
Figueiredo, Flávio de Azevedo
Ramos, Lucas Emanuel Ferreira
Silva, Rafael Tavares
Ponce, Daniela [UNESP]
de Carvalho, Rafael Lima Rodrigues
Schwarzbold, Alexandre Vargas
Maurílio, Amanda de Oliveira
Scotton, Ana Luiza Bahia Alves
Garbini, Andresa Fontoura
Farace, Bárbara Lopes
Título da Revista
ISSN da Revista
Título de Volume
Editor
Resumo
Background: Acute kidney injury (AKI) is frequently associated with COVID-19, and the need for kidney replacement therapy (KRT) is considered an indicator of disease severity. This study aimed to develop a prognostic score for predicting the need for KRT in hospitalised COVID-19 patients, and to assess the incidence of AKI and KRT requirement. Methods: This study is part of a multicentre cohort, the Brazilian COVID-19 Registry. A total of 5212 adult COVID-19 patients were included between March/2020 and September/2020. Variable selection was performed using generalised additive models (GAM), and least absolute shrinkage and selection operator (LASSO) regression was used for score derivation. Accuracy was assessed using the area under the receiver operating characteristic curve (AUC-ROC). Results: The median age of the model-derivation cohort was 59 (IQR 47–70) years, 54.5% were men, 34.3% required ICU admission, 20.9% evolved with AKI, 9.3% required KRT, and 15.1% died during hospitalisation. The temporal validation cohort had similar age, sex, ICU admission, AKI, required KRT distribution and in-hospital mortality. The geographic validation cohort had similar age and sex; however, this cohort had higher rates of ICU admission, AKI, need for KRT and in-hospital mortality. Four predictors of the need for KRT were identified using GAM: need for mechanical ventilation, male sex, higher creatinine at hospital presentation and diabetes. The MMCD score had excellent discrimination in derivation (AUROC 0.929, 95% CI 0.918–0.939) and validation (temporal AUROC 0.927, 95% CI 0.911–0.941; geographic AUROC 0.819, 95% CI 0.792–0.845) cohorts and good overall performance (Brier score: 0.057, 0.056 and 0.122, respectively). The score is implemented in a freely available online risk calculator (https://www.mmcdscore.com/). Conclusions: The use of the MMCD score to predict the need for KRT may assist healthcare workers in identifying hospitalised COVID-19 patients who may require more intensive monitoring, and can be useful for resource allocation.
Descrição
Palavras-chave
Acute kidney injury, COVID-19, Kidney replacement therapy, Risk factors, Risk prediction, Score
Como citar
BMC Medicine, v. 20, n. 1, 2022.